Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Bristol-Myers

Celgene

Gilead Sciences

Johnson & Johnson

Pfizer

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

Big Drugmakers That May Tread the M&A Path After Pfizer

Biogen

Pfizer could be only the first of several to spend billions buying smaller biotech.

3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal

Alphabet

W. P. Carey

When your time frame is decades, you need to look differently at an investment. Here are three that can stand the test of time.

Thee Stocks to Buy and Hold for the Next 50 Years.

Allergan

FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

ABIOMED

Stryker

Teladoc

These beaten-down healthcare stocks still have plenty of long-term potential. Here's what investors need to know about each.

5 Healthcare Stocks to Pick Up From the Wreckage

Amgen announced positive results from a phase 1 study using AMG 510 to treat patients with KRASG12C mutant solid tumors.

Amgen Breaches Hurdle For Decades Of Research To Bring A New Drug To Reality

AstraZeneca

Merck

Novartis

Roche Holding AG

Sanofi

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Amgen Inc. AMGN, +1.38% said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma (R/R MM) showed that serious adverse events were reported in 19 of 42 patients (45%), with 16 requiring hospitalization.

Amgen's early-stage study of cancer treatment had 'adverse events' in nearly half of its patients

Amgen Inc. (NASDAQ:AMGN) has accomplished something cancer researchers have failed to do for decades.

Amgen Drug Breaks New Ground

It has been a tough year for many members of the so-called big pharma and big biotech.

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

Mirati Therapeutics

Mirati Therapeutics Inc (NASDAQ: MRTX)'s shares have been on a tear, advancing over 50 percent since Amgen, Inc.

How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.

3 Cancer Stocks Given a Lift by Amgen

Which of these elite biotechs is the better buy right now?

Biogen vs. Amgen

Amgen stock popped Monday after its experimental drug showed promise in hard-to-treat lung and colon cancers. The FDA granted the drug, AMG 510, orphan drug designation in both caners.

Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Apple

Bank of America

Citigroup

Cisco Systems

JPMorgan Chase & Co

Microsoft

Oracle

Wells Fargo

The top ten stock buybacks by S&P 500 companies in 2018 totaled $252 billion. Here are the best stocks to buy of the bunch.

Ranking the Top 10 Stock Buybacks of Last Year

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 4% Since Last Earnings Report: Can It Rebound?

These charts show there's a new Amgen emerging.

3 Charts Every Amgen Investor Needs to See

After quite some time of muted or negative performance, big biotech may be worth a look again.

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

Amgen (AMGN) Offers to Acquire Drug Discovery Platform

Amgen, Inc. took a logical step forward in buying a preclinical biotech it has been collaborating with since 2016.

Amgen To Buy Danish Collaborator Nuevolution For $167M

Emergent BioSolutions

Invesco Advantage Municipal Income Trust II

These three biotech stocks could be prime comeback candidates.

3 Top Biotech Stocks  to Buy in May

Amgen stock toppled to a year-low Wednesday after first-quarter competition snagged a key blockbuster drug. Further, sales of key drugs Aimovig and Repatha lagged analyst expectations.

Amgen Earnings Beat Forecasts — But Here's The Caveat You Need To Know

Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same.  The company raises the lower end of its previously issued sales and earnings guidance for 2019.

Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure

Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2019 Results - Earnings Call Transcript

News for Amgen Stock (AMGN)